Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 5/20 | 0.45 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15761354 | 0.92 | KIF11 (0.39) | KCNN4KIF11KCNH2HTR2AHTR2C | |
| SCHEMBL2406465 | 0.86 | KCNN4 (0.42) | KCNN4KIF11KCNH2HTR2AHTR2C | |
| SCHEMBL18847229 | 0.86 | KIF11 (0.43) | KCNN4KIF11CYP3A4CYP2C9HTT | |
| SCHEMBL18848228 | 0.85 | KIF11 (0.45) | KCNN4KIF11CYP3A4CYP2C9HTT | |
| SCHEMBL20341164 | 0.85 | KIF11 (0.45) | KCNN4KIF11CYP3A4CYP2C9HTT | |
| SCHEMBL22828015 | 0.85 | KIF11 (0.45) | KCNN4KIF11CYP3A4CYP2C9HTT | |
| SCHEMBL18558846 | 0.85 | KIF11 (0.45) | KCNN4KIF11CYP3A4CYP2C9HTT | |
| SCHEMBL21385478 | 0.85 | KIF11 (0.45) | KCNN4KIF11CYP3A4CYP2C9HTT | |
| SCHEMBL3950448 | 0.84 | KIF11 (0.47) | KCNN4KIF11KCNH2CYP3A4CYP2C9 | |
| SCHEMBL26811331 | 0.83 | KIF11 (0.40) | KCNN4KIF11KCNH2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1932853-A1 | Novel depsipeptides and process for preparing same | Cubist Pharmaceutical Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20080119395-A1 | Novel Depsipeptides and Process for Preparing Same | CUBIST PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| EP-1814588-A2 | ANTIINFECTIVE LIPOPEPTIDES | Cubist Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006110185-A2 | ANTIINFECTIVE LIPOPEPTIDES | CUBIST PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | CUBIST PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| EP-1423414-A4 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | CUBIST PHARM INC (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1423414-A1 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | Cubist Pharmaceuticals, Inc. (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030083240-A1 | Novel depsipeptides and process for preparing same | CUBIST PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003014147-A1 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | CUBIST PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083240-A1 | Novel depsipeptides and process for preparing same | VIP, DNPEP, PREP | KCNN4 4605/4885KIF11 1722/4885KCNH2 4263/4885 |
| US-20080051326-A1 | Antiinfective Lipopeptides | VIP, NGLY1, PREP | KCNN4 4642/4885KIF11 4332/4885KCNH2 4383/4885 |
| US-20060194714-A1 | Novel depsipeptides and process for preparing same | VIP, DNPEP, PREP | KCNN4 4605/4885KIF11 1722/4885KCNH2 4263/4885 |
| US-20080119395-A1 | Novel Depsipeptides and Process for Preparing Same | VIP, DNPEP, PREP | KCNN4 4605/4885KIF11 1722/4885KCNH2 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.